Healthcare / BiotechnologyNasdaqCM
$16.61
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-232.8M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
1/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-47.4%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-342.6M · FCF $-276.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | $4.0M | $3.5M | $2.5M | $4.3M | $4.3M |
| Net Income | $-342.6M | $-342.6M | $-269.9M | $-237.7M | $-129.9M | $-79.4M | $-110.7M | $-41.9M | $-32.7M | $-26.5M | $-17.3M | $-11.3M | $-7.9M | $-2.2M |
| EBITDA | $-362.9M | $-362.9M | $-298.5M | $-253.9M | $-134.0M | $-79.6M | $-110.1M | $-41.7M | $-32.8M | $-26.2M | $-16.6M | $-11.0M | $-6.7M | $-49000.00 |
| EPS | — | — | — | -5.31 | -4.05 | -6.66 | -31.13 | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | -662.8% | -488.6% | -440.8% | -159.0% | -4.6% |
| Net Margin | — | — | — | — | — | — | — | — | — | -662.3% | -496.8% | -446.3% | -182.6% | -50.0% |
| Balance Sheet | ||||||||||||||
| Debt/Equity | — | — | 0.03 | 0.05 | 0.01 | 0.00 | — | 0.49 | 0.19 | 0.26 | — | — | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-276.9M | $-276.9M | $-232.8M | $-185.1M | $-94.6M | $-54.9M | $-29.8M | $-36.1M | $-27.3M | $-28.4M | $-15.0M | $-7.0M | $-2.5M | $-1.2M |
| Returns | ||||||||||||||
| ROE | -47.4% | -47.4% | -40.2% | -53.8% | -32.9% | -42.3% | -92.2% | -265.8% | -63.7% | -68.8% | 27.9% | 25.0% | -131.7% | 9.0% |
| Growth & Yield | ||||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | — | — | 15.1% | 37.0% | -41.3% | 0.1% | — |
| EPS Growth | — | — | — | -31.1% | 39.2% | 78.6% | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.